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Fixing conformation by introducing a ring structure is a common strategy in drug development. We 
demonstrate a synthesis that installs a small carbocyclic ring as a structurally-rigid unit in drug lead 
compounds. Both trans- and cis-cyclobutane rings were constructed in excellent selectivities by controlling 
the reaction temperature of an EtAlCl2-catalyzed [2+2] cycloaddition between a silyl enol ether and an 
α,β-unsaturated ester. Spirocyclopropane rings were stereospecifically formed by our previously reported 
ring-contraction rearrangement of fused cyclobutanols. This strategy allowed stereodivergent access to a new 
class of steroidal derivatives bearing a small ring. 
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Rational drug design using protein crystal structures is a rapidly growing area in which several 
drug discovery success stories have emerged in recent decades. Once the structure of the binding site of the 
receptor or enzyme is identified, discovery of new small molecule drug leads can be accelerated by using 
computer simulations such as docking studies. The X-ray crystallographic structure also provides a great 
opportunity for the optimization of the structure of late-stage leads. For example, the spatial arrangement of 
the functional groups can be finely tuned at sub-angstrom (Å) resolution in accordance with the 
crystallographic structure of the binding site. Conformational fixation of flexible drug leads is a popular 
tactic used to increase activity and/or reduce side effects. A rotatable side chain on the drug scaffold can be 
restricted by incorporating a structurally rigid moiety such as a double bond, alkyne, amide or aromatic ring. 
Small-membered carbocycles such as cyclopropane and cyclobutane rings are also used to restrict rotatable 
side chains in drug development, owing to their structural rigidity.1 However, limited numbers of these exist, 
probably because of the lack of practical and stereoselective synthetic methods.2  
We have reported several unique synthetic methods to construct a cyclobutane ring or a 
spirocyclopropane ring bearing several functional groups with high stereoselectivity. Catalytic [2+2] 
cycloaddition of readily available silyl enol ethers and α,β-unsaturated esters in the presence of an acid 
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catalyst, such as EtAlCl2 and triflic imide (Tf2NH), affords functionalized cyclobutanes (Scheme 1A).3 The 
cycloaddition occurs through a stepwise Michael–aldol addition pathway in a diastereoselective manner. A 
stereospecific ring-contraction rearrangement of fused cyclobutanols to give spirocyclopropanes was also 
reported (Scheme 1B).4 This rearrangement proceeds through a tertiary carbocationic intermediate, which 
then undergoes rearrangement of the adjacent carbon–carbon bond with release of strain energy.  
 































We envisaged application of this methodology to the stereoselective synthesis of drug derivatives, 
incorporating a cyclobutane ring or a spirocyclopropane moiety to restrict the conformation. A steroidal 
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scaffold was chosen as a model drug lead. Steroids are a family of bioactive compounds composed of a 
unique fused ring system and are widely used as drugs. However, the side effects sometimes become a 
limiting problem because they have diverse biological activities. For example, calcitriol, which has a 
steroidal backbone with an opened B-ring, modulates a broad range of biological functions such as bone 
homeostasis, immunity, cellular growth and differentiation through binding to the vitamin D receptor.5 
Although synthetic analogues of calcitriol are effective in the treatment of osteoporosis and psoriasis,6 their 
therapeutic use is limited by severe side effects such as hypercalcemia and hypercalciuria.5c Thus, a number 
of calcitriol analogues have been synthesized to discover which ones display biological activities and reduced 
side effects better than natural steroid hormones.5c,7 Mouriño reported calcitriol analogues with a locked side 
chain by introducing an unsaturated bond or an additional ring.8 Some of the analogues exhibited significant 
biological activities, such as the induction of the transcriptional activity of vitamin D receptors in human 
colon cancer cells.8c Herein, we report a stereodivergent synthesis of steroidal derivatives bearing a small 
ring using a [2+2] cycloaddition and stereospecific ring-contraction rearrangement. During the course of our 
synthetic study, switching the diastereoselectivity of the [2+2] cycloaddition depending on the reaction 
temperature was observed. The mechanistic insight of this is also discussed.9 
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2. Results and discussion 
At the outset of the study, the [2+2] cycloaddition of silyl enol ether 1, prepared from estrone 
3-methyl ether, with methyl acrylate (2a) was investigated (Table 1). When silyl enol ether 1 was treated with 
1.3 equivalents of 2a at −78 °C in the presence of 1.0 mol% of Tf2NH, cyclobutane cis-3a was afforded in 
only 5% yield (entry 1). There was a decrease or slight increase in yield when using more equivalents of 
Tf2NH and methyl acrylate (entries 2–4). Reaction with 1,1,3,3-tetrakis(triflyl)propane (Tf2CHCH2CHTf2)10 
resulted in no significant improvement in yield (entry 5), whereas EtAlCl2 was an effective catalyst and 
afforded cis-3a in 77% yield (entry 6).  
 

















entry catalyst (mol%) 2a (equiv) time (h) yield of cis-3a (%)a 
1 Tf2NH (1.0) 1.3 2.5 5 
2 Tf2NH (5.0) 1.3 2.5 4 
3 Tf2NH (5.0) 2.5 1.0 33 
4 Tf2NH (20) 2.5 2.0 10 
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5 Tf2CHCH2CHTf2 (20) 2.5 2.0 17 
6 EtAlCl2 (20) 2.0 2.0 77 
a Isolated yields. 
 
Interestingly, when using hexafluoroisopropyl (HFIP) acrylate (2b) instead of 2a, we observed that 
the diastereoselectivity in the [2+2] cycloaddition switched depending on the reaction conditions (Table 2). 
Treatment of silyl enol ether 1 with 2b in the presence of EtAlCl2 at −78 °C produced trans-3b in 85% yield 
with high diastereoselectivity (entry 1). The trans-selectivity remained approximately constant regardless of 
the reaction time (entries 1 and 2). In contrast, the trans-selectivity of 3b decreased with an increase in 
reaction temperature (entries 1, 3–5). When the reaction was carried out at room temperature, cis-3b was 
obtained exclusively in 74% yield along with 12% yield of the Michael adduct 4 (entry 5). The reaction 
conducted at −78 °C for 10 min, followed by stirring at room temperature for an additional 10 min, afforded 
only the cis-adduct (entry 6). The results clearly indicate that trans-3b is the kinetically favored product 
whereas cis-3b is the thermodynamically more stable one. Reactions with methyl acrylate (2a) at both room 
temperature (rt) and −78 °C afforded cis-3a exclusively (entry 8 and Table 1 entry 6). Even when the reaction 
temperature was lowered to −90 °C, trans-3a was obtained only as a minor diastereomer (entry 7). It appears 
that the activation energy required for isomerization of trans-3 to cis-3 is dependent on the ester substituent. 
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2a: R = Me
2b: R = CH(CF3)2
 
entry acrylate 2 temp. (°C) time (min) yield of 3 (%)a trans:cis 
1 2b −78 10 85 95:5 
2 2b −78 120 89 94:6 
3 2b −60 10 86 64:36 
4 2b −40 10 89 5:95 
5 2b rt 120 74b 0:100 
6 2b −78 then rt 10 then 10 70b 0:100 
7 2a −90 10 77 35:65 
8 2a rt 120 72 0:100 
a Isolated yields. b Michael adduct 4 was obtained in 5–12 % yield. 
 
Crossover experiments were performed to investigate the diastereoselectivity switch further. 
Treatment of trans-3b with EtAlCl2 at ambient temperature resulted in complete conversion into cis-3b 
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(Scheme 2, eq 1), whereas no reaction occurred in the absence of EtAlCl2. Using the same catalyst at the 
same temperature, cis-3b did not isomerize to trans-3b. When a mixture of the methyl ester cis-3a and an 
equimolar of HFIP acrylate (2b) was treated with EtAlCl2 at ambient temperature, the crossover adduct 
cis-3b was afforded in 35% yield as a single diastereomer, along with 35% yield of recovered cis-3a (eq 2). 
These results indicate that EtAlCl2 promotes the retro [2+2] process to reproduce silyl enol ether 1 and 
acrylate 2. HFIP acrylate (2b) competes with in situ generated methyl acrylate (2a) in the [2+2] cycloaddition 
of the regenerated silyl enol ether 1, which results in the isolation of a mixture of cis-3a and cis-3b. In 
contrast, the reaction of methyl ester cis-3a at −40 °C did not provide the crossover adduct, but rather the 
ring-opened product 4a in 30% yield (eq 3). In the reaction of a mixture of trans- and cis-3a at −40 °C, 
epimerization of trans-3a into cis-3a occurred along with the formation of 4a, but no crossover product was 
observed (eq 4). 
 

































































Based on the above results, a possible mechanism for the EtAlCl2-catalyzed [2+2] cycloaddition of 
1 is shown in Figure 1. Michael addition of silyl enol ether 1 to acrylate 2 proceeds predominantly at the less 
hindered α-face to give zwitterionic intermediate 5. At lower temperatures, intramolecular aldol-type 
addition of 5 takes place via the preferred transition state TS-I to give trans-3, whereas less favored TS-II 
affords cis-3 because of steric effects. The product trans-3 would be less stable than cis-3 because of steric 
repulsion between the axial hydrogen atom at the C14 position and the ester moiety, which is supported by 
DFT calculations of cis- and trans-3b (∆G°cis–trans = −12.6 kJ/mol).11 The epimerization process is rather 
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complicated. At ambient temperature, trans- and cis-3 equilibrate through a retro [2+2] cycloaddition via 
silyl enol ether 1 to provide the thermodynamically more stable cis-3. In contrast, the retro [2+2] 
cycloaddition does not proceed at −40 °C, which indicates that the epimerization to cis-3 at this temperature 
occurs via siloxonium ion 5 through a retro aldol reaction. In addition, ketone 4 was presumably formed by 
desilylation of ketene silyl acetal 6 during work-up. 
 



























–90 °C for 2a
 

























With the cyclobutane scaffolds constructed, we next investigated the ring-contraction 
rearrangement of cyclobutanols to give spirocyclopropanes (Scheme 3). To prepare the substrate for the 
ring-contraction rearrangement, trans-3b was treated with Red-Al to afford cyclobutanol trans-7 in 89% 
yield. Removal of the tert-butyldimethylsilyl (TBS) group on the tertiary hydroxyl function followed by 
benzoyl protection of the primary hydroxyl group furnished trans-9. Cis-9 was also prepared through the 
same procedure from cis-3b. With the substrates 9 for the ring contraction reaction in hands, the reaction 
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conditions was firstly screened by using cis-9. According as our previous conditions,4 cis-9 was treated with 
methanesulfonyl chloride (MsCl) in 2,6-lutidine, which resulted in the formation of the mesylated product 
(ca. 30%), along with recovered starting material (ca. 40%). We tried other conditions such as oxalyl 
chloride/triethylamine and triflic anhydride/triethylamine to convert the tertiary hydroxyl group to a good 
leaving group; however, these attempts proved unsuccessful, and no spirocyclopropane product was observed. 
The ring contraction rearrangement of cis-9 was finally achieved by using thionyl chloride/triethylamine to 
afford (20S)-10 in 87% yield (16β:16α = 4:1), the relative configuration was determined by the NOE 
Spectroscopy. The same conditions were successfully applied to the rearrangement of trans-9 to afford 
(20R)-10 in a stereospecific manner, albeit in lower yield (66%, 16β:16α = 7:3). In these reactions, the 
carbocationic intermediates predominantly undergo nucleophilic attack by the chloride ion to afford (20S)- or 
(20R)-10, and no elimination products are observed. The difference in yield between (20S)- and (20R)-10 
was due to the formation of byproduct 11. We do not fully understand why the ring-contraction 
rearrangement of trans-9 yielded this unusual product, but it may be influenced by the dihedral angle 
between the migrating carbon–carbon bond and the empty p-orbital of the carbocationic intermediate.  
 



















































With the estrone derivatives bearing a small ring in hand, our attention turned toward the 
installation of a cholestane side chain (Scheme 4). Initially, removal of the benzoyl group and dechlorination 
of (20S)-10 were performed in one-pot using Red-Al to give cyclopropanol (20S)-12, which was then 
subjected to Swern oxidation to afford aldehyde (20S)-13. Extension of the carbon chain was accomplished 
by one-pot Julia olefination of the aldehyde using benzothiazolyl sulfone 15, which was prepared from 
3-methyl-1,3-butanediol in five steps (Scheme 5). Triethylsilyl (TES) protection of 15 was necessary for 
complete conversion of the starting aldehydes in the olefination reactions. Reduction of olefin 16 was 
unsuccessfully attempted by hydrogenation using Pd/C in ethyl acetate, which resulted in simultaneous 
ring-opening of the cyclopropane. Accordingly, several catalysts were tested for the chemoselective 
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hydrogenation. Reduction with Pd/Fib or Pd/C(en) gave a cyclopropane ring-opened product with the intact 
carbon–carbon double bond. No reaction occurred using Pd/MS5A13 or Pd/BN14 in methanol. In the reaction 
with Rh/alumina in ethyl acetate, the double bond was reduced without ring-opening of the cyclopropane, but 
the aromatic A-ring was also reduced to a cyclohexane ring. Although these efforts using heterogeneous 
catalysts were unfruitful, chemoselective reduction of the olefin was achieved by diimide reduction,15 which 
was followed by removal of the TES group to give (20S)-17. The final deprotection of the methyl group was 
troublesome. Treatment with BBr3 or reagents such as TMSI, NaSEt, or AlMe3/NaI16 gave a complex mixture, 
probably due to instability of the spirocyclopropane. Nevertheless, the deprotection was accomplished by 
using n-BuLi/PPh2H17 to give the final product (20S)-18 in 76% yield. (20R)-18 was also synthesized by the 
similar procedure. It is worth noting that treatment of (20R)-10 with Red-Al gave a considerable amount of 
byproducts. Reduction with sodium borohydride in DMSO at 130 °C gave (20R)-12 in 53% yield with less 
byproduct formation.12 
 








































































1) NaI, acetone, reflux
2)
3) mCPBA, CH2Cl2












Installation of the side chain onto the cyclobutane ring was also accomplished using a similar 
strategy (Scheme 6). Swern oxidation followed by one-pot Julia olefination of trans- and cis-7 afforded 
cyclobutanes trans- and cis-19, respectively. Reduction of the resulting olefin and removal of the TES group 
were carried out in one-pot by hydrogenation with palladium on carbon. Cleavage of the methyl and TBS 
groups completed the synthesis of trans- and cis-22, and the structures were verified by X-ray 
crystallography. 
 
Scheme 6. Installation of a Side Chain and Completion of the Synthesis of trans- and cis-22 
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Pd/C, H2
 (1 atm) BuLi, PPh2H
trans-7
1) (COCl)2, DMSO    NEt
3, CH2Cl2, –78 °C
2) LiHMDS, 15    T F, –78 °C
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We have demonstrated the synthesis of four cholestane-type steroidal compounds bearing a cyclobutane or a 
spirocyclopropane skeleton. The described route features a diastereo-switchable [2+2] cycloaddition reaction 
and a stereospecific ring-contraction to construct small rings in a stereo-divergent manner. The 
diastereoselectivity in the [2+2] cycloaddition was inverted under kinetic or thermodynamic conditions. A 
carbon side chain was installed on the small rings using a one-pot Julia olefination followed by reduction of 
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the resulting olefin. This strategy provides a facile route to access a new class of steroid derivatives bearing a 
small ring. Biological evaluation of the synthetic steroids is currently underway. 
 
4. Experimental Section 
4.1. General Remarks 
All non-aqueous reactions were carried out under a positive atmosphere of argon in dried glassware. 
Dehydrated solvents were purchased for the reactions and used without further desiccation. Reagents were 
purchased and used without further purification, unless otherwise stated. Reactions were monitored by 
thin-layer chromatography (TLC) carried out on Merck TLC silica gel 60 F254. Column chromatography was 
performed using Fuji Silysia BW-200 silica gel. Nuclear magnetic resonance (NMR) spectra were recorded 
on a JEOL JNM-ECA 500 instrument. The 1H chemical shifts were calibrated with internal tetramethylsilane 
(TMS, 0 ppm) in deuterated organic solvents. The 13C chemical shifts are reported relative to CDCl3 (77.0 
ppm), DMSO-d6 (39.5 ppm), acetone-d6 (206.7 and 30.4 ppm), MeOH-d4 (49.0 ppm) or THF-d8 (67.4 and 
25.3 ppm). The following abbreviations were used to explain NMR peak multiplicities: s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet, br = broad. Low-resolution mass spectra (LRMS) were 
recorded on a SHIMADZU GCMS-QP2010 SE spectrometer (EI) or a JEOL MS700 spectrometer (FAB). 
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High-resolution mass spectra (HRMS) were recorded on a JEOL MS700 spectrometer (FAB) or a 
SHIMADZU LCMS-IT-TOF fitted with an ESI. IR experiments were recorded on a SHIMADZU 
IRAffinity-1 spectrometer. The wave numbers of maximum absorption peaks of IR spectroscopy are 
presented in cm–1. All melting points were determined using a Yamato MP-21 melting point apparatus and 
are uncorrected. Optical rotations were obtained on a JASCO P-1030 polarimeter. X-ray diffraction data were 
recorded on a RIGAKU R-AXIS RAPID system. Compounds 1,9 cis-3a,9 trans-3b,9 cis-3b,9 4a9 and 
dipotassium azodicarboxylate18 were prepared according to previous procedures. 
 
4.2 Experimental Procedures 
4.2.1. Synthesis of 
((6bS,8aS,8bR,9S,10aS,11aS,11bR)-8b-((tert-butyldimethylsilyl)oxy)-4-methoxy-8a-methyl-2,6b,7,8,8a,8b,9,1
0,10a,11,11a,11b-dodecahydro-1H-cyclobuta[3,4]cyclopenta[1,2-a]phenanthren-9-yl)methanol (trans-7). To 
a solution of a mixture of trans- and cis-3b (21.0 g, 33.8 mmol, 9:1) in toluene (135 mL) was added a 3.6 M 
solution of Red-Al in toluene (24 mL, 86 mmol) at 0 °C under argon. After being stirred for 3 h, the reaction 
mixture was quenched with saturated aqueous Rochell salt, and stirred vigorously for 30 min. The aqueous 
layer was extracted with EtOAc, and the combined organic layers were washed with brine, and dried over 
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Na2SO4. Concentration under reduced pressure gave a white solid, which was purified by column 
chromatography (hexane/EtOAc 9:1) to afford trans-7 (12.4 g, 80%) as a white solid along with cis-7 (1.39 g, 
9%). Analytical sample was obtained by recrystallization from hexane/EtOAc as white blocks; Found: C, 
73.38; H, 9.93. C28H44O3Si requires C, 73.63; H, 9.71%; Mp 189–191 °C; [α]D20 +14.2 (c 1.00, CHCl3); νmax 
(CHCl3) 3494 (br), 2949, 2855, 1250 cm–1; δH (500 MHz, CDC13) 7.21 (d, J = 8.6 Hz, 1H), 6.72 (dd, J = 8.6, 
2.6 Hz, 1H), 6.64 (d, J = 2.6 Hz, 1H), 4.01 (ddd, J = 10.0, 10.0, 6.0 Hz, 1H), 3.86 (ddd, J = 9.7, 9.7, 5.8 Hz, 
1H), 3.78 (s, 3H), 2.89–2.77 (m, 3H), 2.58–2.51 (m, 1H), 2.36 (ddd, J = 12.0, 12.0, 9.8 Hz, 1H), 2.30–2.22 
(m, 2H), 1.98–1.89 (m, 1H), 1.81–1.71 (m, 2H), 1.62–1.34 (m, 6H), 1.22 (br s, 1H), 0.97 (ddd, J = 12.9, 8.6, 
4.9 Hz, 1H), 0.90 (s, 9H), 0.74 (s, 3H), 0.22 (s, 3H), 0.13 (s, 3H); δC (125 MHz, CDCl3) 157.4, 138.0, 132.6, 
126.4, 113.8, 111.5, 90.4, 62.7, 55.2, 50.6, 48.3, 47.5, 43.9, 41.6, 38.9, 33.2, 31.9, 29.9, 27.9, 26.5, 25.8, 24.6, 
18.2, 17.2, –2.7, –3.1; m/z (EI) 456 (M), 441 (M–Me). 
 
4.2.2. Synthesis of 
((6bS,8aS,8bR,9R,10aS,11aS,11bR)-8b-((tert-butyldimethylsilyl)oxy)-4-methoxy-8a-methyl-2,6b,7,8,8a,8b,9,1
0,10a,11,11a,11b-dodecahydro-1H-cyclobuta[3,4]cyclopenta[1,2-a]phenanthren-9-yl)methanol (cis-7). To a 
solution of cis-3b (8.04 g, 13.0 mmol) in toluene (65 mL) was added 3.6 M Red-Al in toluene (9.0 mL, 32 
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mmol) at 0 °C under argon. After being stirred for 3 h, the reaction mixture was quenched with saturated 
aqueous Rochell salt, and stirred vigorously for 30 min. The aqueous layer was extracted with EtOAc, and 
the combined organic layers were washed with brine, and dried over Na2SO4. Concentration under reduced 
pressure gave a white solid, which was purified by column chromatography (hexane/EtOAc 9:1) to afford 
cis-7 (5.17g, 87%) as a white solid. Analytical sample was obtained by recrystallization from hexane/EtOAc 
as white blocks; Found: C, 73.36; H, 9.91. C28H44O3Si requires C, 73.63; H, 9.71%; Mp 204–205 °C; [α]D20 
+29.2 (c 1.00, CHCl3); νmax (CHCl3) 3500 (br), 2929, 2856, 1253 cm–1; δH (500 MHz, CDC13) 7.22 (d, J = 
8.6 Hz, 1H), 6.72 (dd, J = 8.6, 2.6 Hz, 1H), 6.64 (d, J = 2.6 Hz, 1H), 3.83 (ddd, J = 10.9, 10.9, 2.3 Hz, 1H), 
3.78 (s, 3H), 3.49 (ddd, J = 10.9, 10.9, 5.8 Hz, 1H), 2.89–2.86 (m, 2H), 2.78–2.67 (m, 1H), 2.66–2.59 (m, 
1H), 2.41–2.31 (m, 1H), 2.25 (ddd, J = 10.9, 10.9, 3.4 Hz, 1H), 1.94–1.83 (m, 2H), 1.81 (dd, J = 10.9, 1.7 Hz, 
1H), 1.71–1.59 (m, 3H), 1.53–1.40 (m, 5H), 1.29 (ddd, J = 12.4, 9.2, 2.9 Hz, 1H), 0.94 (s, 9H), 0.73 (s, 3H), 
0.30 (s, 3H), 0.16 (s, 3H); δC (125 MHz, CDCl3) 157.4, 137.9, 132.7, 126.4, 113.8, 111.4, 90.7, 63.8, 55.2, 
47.9, 46.4, 44.1, 39.3, 38.9, 38.4, 31.9, 29.8, 29.7, 27.7, 26.1, 26.0, 24.2, 18.4, 14.5, –1.2, –2.3; m/z (FAB) 
457 (M+H). 
 
4.2.3. Synthesis of 
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(6bS,8aS,8bR,9S,10aS,11aS,11bR)-9-(hydroxymethyl)-4-methoxy-8a-methyl-1,2,6b,7,8,8a,9,10,10a,11,11a,11
b-dodecahydro-8bH-cyclobuta[3,4]cyclopenta[1,2-a]phenanthren-8b-ol (trans-8). A mixture of trans-7 (7.74 
g, 16.9 mmol) and a 1.0 M solution of TBAF in THF (51 mL, 51 mmol) was heated under reflux for 46 h. 
After cooling to room temperature, the resulting mixture was diluted with CHCl3, and washed with water. 
The aqueous layer was extracted with CHCl3, dried over Na2SO4. Concentration in vacuo and purification by 
column chromatography (EtOAc) gave trans-8 (4.30 g, 75%) as a pale yellow solid. Analytical sample was 
obtained by recrystallization from EtOAc as a white needle; Found: C, 77.16; H, 8.83. C22H30O3 requires C, 
76.88; H, 9.00%; Mp 199–201 °C; [α]D20 +25.2 (c 1.00, THF); νmax (CHCl3) 3287 (br), 2974, 2924, 2859, 
1709, 1636, 1501, 1350, 1254, 1184 cm–1; δH (500 MHz, CDC13) 7.21 (d, J = 8.9 Hz, 1H), 6.72 (dd, J = 8.5, 
2.4 Hz, 1H), 6.64 (d, J = 2.3 Hz, 1H), 4.04 (dd, J = 8.9, 8.9 Hz, 1H), 3.84 (dd, J = 8.6, 8.6 Hz, 1H), 3.78 (s, 
3H), 2.89–2.76 (m, 3H), 2.42–2.25 (m, 4H), 1.96–1.91 (m, 2H), 1.88 (ddd, J = 11.5, 11.5, 5.7 Hz, 1H), 1.79 
(ddd, J = 12.0, 3.6, 3.3 Hz, 1H), 1.72 (ddd, J = 12.7, 12.7, 3.9 Hz, 1H), 1.57–1.36 (m, 6H), 1.03–0.95 (m, 
1H), 0.84 (s, 3H); δC (125 MHz, DMSO-d6) 157.0, 137.5, 132.2, 126.2, 113.4, 111.5, 87.2, 60.9, 54.8, 50.2, 




4.2.4. Synthesis of 
(6bS,8aS,8bR,9R,10aS,11aS,11bR)-9-(hydroxymethyl)-4-methoxy-8a-methyl-1,2,6b,7,8,8a,9,10,10a,11,11a,11
b-dodecahydro-8bH-cyclobuta[3,4]cyclopenta[1,2-a]phenanthren-8b-ol (cis-8). A mixture of cis-7 (34.4 g, 
75.4 mmol) and a 1.0 M solution of TBAF in THF (226 mL, 226 mmol) was stirred at room temperature for 
20 h. The resulting mixture was diluted with CHCl3, and washed with water. The aqueous layer was extracted 
with CHCl3, dried over Na2SO4. Concentration in vacuo and purification by column chromatography 
(hexane/EtOAc 3:2) gave cis-8 (15.0 g, 83%) as a white solid. Analytical sample was obtained by 
recrystallization from EtOAc as a white needle; Found: C, 77.43; H, 8.89. C22H30O3 requires C, 77.16; H, 
8.83%; Mp 203–205 °C (dec.); [α]D20 +36.5 (c 1.00, CHCl3); νmax (KBr) 3264 (br), 2932, 2920, 2859, 1609, 
1499, 1236 cm–1; δH (500 MHz, CDCl3) 7.23 (d, J = 8.6 Hz, 1H), 6.73 (dd, J = 8.6, 2.9 Hz, 1H), 6.64 (d, J = 
2.6 Hz, 1H), 3.85–3.74 (m, 2H), 3.78 (s, 3H), 2.93–2.82 (m, 2H), 2.62–2.55 (m, 1H), 2.50 (s, 1H), 2.41–2.32 
(m, 2H), 2.28–2.20 (m, 2H), 2.17–2.09 (m, 1H), 1.97–1.89 (m, 1H), 1.69 (ddd, J = 11.2, 11.2, 5.5 Hz, 1H), 
1.56–1.36 (m, 7H), 1.27 (ddd, J = 12.6, 9.5, 3.5 Hz, 1H), 0.80 (s, 3H); δC (125 MHz, DMSO-d6) 157.0, 137.4, 
132.3, 126.2, 113.4, 111.4, 86.6, 62.3, 54.9, 48.6, 45.4, 43.6, 40.4, 38.3, 37.9, 31.5, 29.4, 29.3, 27.3, 25.8, 
24.9, 13.9; m/z (EI) 342 (M), 324 (M–H2O). 
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4.2.5. Synthesis of 
((6bS,8aS,8bR,9S,10aS,11aS,11bR)-8b-hydroxy-4-methoxy-8a-methyl-2,6b,7,8,8a,8b,9,10,10a,11,11a,11b-do
decahydro-1H-cyclobuta[3,4]cyclopenta[1,2-a]phenanthren-9-yl)methyl benzoate (trans-9). To a suspension 
of trans-8 (3.10 g, 9.05 mmol) and DMAP (112 mg, 0.917 mmol) in CH2Cl2 (36 ml) were added 
triethylamine (2.5 mL, 18 mmol) and benzoyl chloride (1.3 mL, 11 mmol). After being stirred for 2 h at room 
temperature, the reaction mixture was quenched with saturated aqueous NaHCO3. The aqueous layer was 
extracted with EtOAc, and the combined organic layers were washed with brine, and dried over Na2SO4, and 
concentrated in vacuo to give a brown solid. The residue was purified by column chromatography 
(hexane/EtOAc 4:1 to 1:1) to yield trans-9 (3.85 g, 95%) as a white solid. Analytical sample was obtained by 
recrystallization from hexane/EtOAc as a white crystal; Found: C, 77.84; H, 7.67. C29H34O4 requires C, 
78.00; H, 7.67.%; Mp 168–169 °C; [α]D20 +23.3 (c 1.00, CHCl3); νmax (CHCl3) 3491 (br), 2936, 2866, 1713, 
1609, 1501, 1450, 1273, 1219 cm–1; δH (500 MHz, CDCl3) 8.04 (dd, J = 7.9, 1.3 Hz, 2H), 7.56 (tt, J = 7.5, 
1.3 Hz, 1H), 7.44 (dd, J = 7.7, 7.7 Hz, 2H), 7.19 (d, J = 8.6 Hz, 1H), 6.70 (dd, J = 8.7, 2.7 Hz, 1H), 6.63 (d, J 
= 2.6 Hz, 1H), 4.63 (dd, J = 11.2, 7.7 Hz, 1H), 4.58 (dd, J = 10.9, 8.9 Hz, 1H), 3.78 (s, 3H), 3.10–3.03 (m, 
1H), 2.93–2.83 (m, 2H), 2.49–2.41 (m, 2H), 2.33–2.27 (m, 2H), 1.96–1.91 (m, 2H), 1.85–1.80 (m, 1H), 1.71 
(ddd, J = 12.4, 12.4, 2.3 Hz, 1H), 1.62–1.56 (m, 2H), 1.52–1.38 (m, 3H), 1.18–1.10 (m, 1H), 0.86 (s, 3H); δC 
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(125 MHz, CDCl3) 166.6, 157.4, 137.8, 132.9, 132.4, 130.2, 129.5, 128.3, 126.3, 113.7, 111.4, 88.5, 64.4, 
55.1, 48.7, 47.2, 45.7, 43.6, 42.2, 38.9, 32.7, 31.6, 29.8, 27.7, 26.3, 24.1, 16.1; m/z (EI) 446 (M), 428 (M–
H2O). 
 
4.2.6. Synthesis of 
((6bS,8aS,8bR,9R,10aS,11aS,11bR)-8b-hydroxy-4-methoxy-8a-methyl-2,6b,7,8,8a,8b,9,10,10a,11,11a,11b-do
decahydro-1H-cyclobuta[3,4]cyclopenta[1,2-a]phenanthren-9-yl)methyl benzoate (cis-9). To a suspension of 
cis-8 (5.32 g, 15.5 mmol) and DMAP (191 mg, 1.56 mmol) in CH2Cl2 (62 mL) were added triethylamine (4.3 
mL, 31 mmol) and benzoyl chloride (2.2 mL, 19 mmol). After being stirred for 3 h at room temperature, the 
reaction mixture was quenched with saturated aqueous NaHCO3. The aqueous layer was extracted with 
EtOAc, and the combined organic layers were washed with brine, and dried over Na2SO4, and concentrated 
in vacuo to give a brown solid. The residue was purified by column chromatography (hexane/EtOAc 4:1) to 
yield cis-9 (6.25 g, 90%) as a white solid. Analytical sample was obtained by recrystallization from 
hexane/EtOAc as a white crystal; Found C, 77.91; H, 7.81. C29H34O4 requires C, 78.00; H, 7.67%; Mp  126–
128 °C; [α]D20 +38.6 (c 1.00, CHCl3); νmax (CHCl3) 3464 (br), 2932, 2862, 1713, 1605, 1501, 1450, 1277 cm–
1; δH (500 MHz CDCl3) 8.03 (dd, J = 8.3, 1.4 Hz, 2H), 7.58 (tt, J = 7.5, 1.4 Hz, 1H), 7.45 (dd, J = 8.0, 8.0 Hz, 
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2H), 7.15 (d, J = 8.6 Hz, 1H), 6.68 (dd, J = 8.6, 2.9 Hz, 1H), 6.63 (d, J = 2.9 Hz, 1H), 4.75 (dd, J = 11.5, 9.8 
Hz, 1H), 4.24 (dd, J = 11.2, 4.0 Hz, 1H), 3.76 (s, 3H), 2.92–2.77 (m, 3H), 2.43–2.38 (m, 1H), 2.26–2.16 (m, 
2H), 2.10–2.02 (m, 1H), 1.95–1.88 (m, 1H), 1.75–1.67 (m, 1H), 1.60 (ddd, J = 12.3, 12.3, 8.3 Hz, 1H), 1.55–
1.34 (m, 7H), 0.80 (s, 3H); δC (125 MHz, CDCl3) 167.1, 157.4, 137.9, 133.0, 132.5, 130.1, 129.5, 128.4, 
126.2, 113.7, 111.3, 87.1, 65.2, 55.1, 49.7, 46.0, 44.0, 40.0, 38.6, 35.3, 31.4, 29.8, 29.6, 27.6, 26.0, 24.4, 
13.8; m/z (EI) 446 (M). 
 
4.2.7. Synthesis of 
((2'S,8S,9S,13S,14S,16S,17R)-16-chloro-3-methoxy-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydrospiro[cyc
lopenta[a]phenanthrene-17,1'-cyclopropan]-2'-yl)methyl benzoate ((20S)-10). To a solution of cis-9 (6.15 g, 
13.8 mmol) in dichloroethane (69 mL) were added triethylamine (3.8 mL, 28 mmol) and thionyl chloride (2.0 
mL, 28 mmol) under argon. After being stirred at 50 °C for 2 h, the reaction was quenched with saturated 
aqueous NaHCO3. The aqueous layer was extracted with EtOAc, and the combined organic layers were 
washed with brine, dried over Na2SO4, and concentrated in vacuo. The residue was purified by column 
chromatography (hexane/diethyl ether 10:1) to afford (20S)-10 (5.60 g, 87%, dr 4:1) as a white solid. The 
diastereomers were partially separated upon careful column chromatography to obtain an analytical sample. 
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Data for the major diasteromer: Mp 177–179 °C; [α]D20 +54.7 (c 1.00, CHCl3); νmax (CHCl3) 2932, 2859, 
1717, 1609, 1501, 1450, 1258, 1177, 1111 cm–1; δH (500 MHz, CDCl3) 8.09 (dd, J = 8.3, 1.2 Hz, 2H), 7.56 (tt, 
J = 7.5, 1.5 Hz, 1H), 7.45 (dd, J = 8.1, 8.1 Hz, 2H), 7.19 (d, J = 8.6 Hz, 1H), 6.71 (dd, J = 8.6, 2.9 Hz, 1H), 
6.64 (d, J = 2.6 Hz, 1H), 4.74 (dd, J = 11.7, 6.0 Hz, 1H), 4.44 (dd, J = 11.5, 8.6 Hz, 1H), 4.32 (dd, J = 8.3, 
5.2 Hz, 1H), 3.78 (s, 3H), 2.94–2.82 (m, 2H), 2.78 (ddd, J = Hz, 13.5, 8.0, 8.0 Hz, 1H), 2.34–2.26 (m, 1H), 
2.25–2.17 (m, 1H), 2.00 (ddd, J = 13.5, 13.5, 5.4 Hz, 1H), 1.93–1.85 (m, 1H), 1.58–1.35 (m, 5H), 1.31–1.22 
(m, 2H), 1.17 (s, 3H), 1.08 (ddd, J = 12.9, 12.9, 4.1 Hz, 1H), 0.49 (dd, J = 5.7, 5.7 Hz, 1H); δC (125 MHz, 
CDCl3) 166.7, 157.5, 137.8, 132.8, 132.2, 130.6, 129.6, 128.3, 126.2, 113.8, 111.6, 67.0, 66.8, 55.2, 52.5, 
43.8, 43.7, 42.4, 39.6, 39.0, 32.8, 29.7, 27.6, 25.7, 19.3, 18.9, 17.7; m/z (EI) 464 (M), 429 (M–Cl), 342 (M–
BzOH), 307 (M–Cl–BzOH); HRMS (ESI): [M+Na]+, found 487.2018. C29H33ClO3Na requires 487.2010. 
 
4.2.8. Synthesis of 
((2'R,8S,9S,13S,14S,16S,17R)-16-chloro-3-methoxy-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydrospiro[cyc
lopenta[a]phenanthrene-17,1'-cyclopropan]-2'-yl)methyl benzoate ((20R)-10) and 
2-chloro-2-((6bS,8aS,8bS,9aS,10aS,10bS)-4-methoxy-8a-methyl-1,6b,7,8,8a,9,9a,10,10a,10b-decahydrocyclo
propa[3,4]cyclopenta[1,2-a]phenanthren-8b(2H)-yl)ethyl benzoate (11). To a solution of trans-9 (1.51 g, 
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3.38 mmol) in dichloroethane (17 mL) were added triethylamine (0.93 mL, 6.7 mmol) and thionyl chloride 
(0.49 mL, 6.8 mmol) under argon. After being stirred at 50 °C for 2 h, the reaction was quenched with 
saturated aqueous NaHCO3. The aqueous layer was extracted with EtOAc, and the combined organic layers 
were washed with brine, dried over Na2SO4, and concentrated in vacuo. The residue was purified by column 
chromatography (hexane/diethyl ether 10:1) to afford (20R)-10 (1.03 g, 66%, dr 7:3) as a white solid and 11 
(173 mg, 11%) as a pale yellow oil. The diastereomers were partially separated upon careful column 
chromatography to obtain an analytical sample. Data for the major diasteromer: Mp 60–63 °C; [α]D20 +29.3 
(c 1.00, CHCl3); νmax (CHCl3) 2936, 1717, 1609, 1501, 1450, 1273, 1111 cm–1; δH (500 MHz, CDCl3) 8.09 (d, 
J = 7.2 Hz, 2H), 7.57 (t, J = 6.9 Hz, 1H), 7.46 (dd, J = 8.0, 8.0 Hz, 2H), 7.19 (d, J = 8.6 Hz, 1H), 6.72 (dd, J 
= 8.3, 2.6 Hz, 1H), 6.64 (d, J = 2.3 Hz, 1H), 4.51 (dd, J = 11.2, 8.3 Hz, 1H), 4.40 (dd, J = 11.5, 7.5 Hz, 1H), 
3.96 (dd, J = 8.0, 6.3 Hz, 1H), 3.78 (s, 3H), 2.94–2.82 (m, 2H), 2.70–2.63 (m, 1H), 2.34–2.21 (m, 2H), 1.98–
1.82 (m, 3H), 1.65 (ddd, J = 11.8, 3.2, 3.2 Hz, 1H), 1.58–1.36 (m, 5H), 1.17 (s, 3H), 1.13 (dd, J = 5.2, 5.2 Hz, 
1H), 0.79 (dd, J = 9.5, 4.9 Hz, 1H); δC (125 MHz, CDCl3) 166.6, 157.5, 137.7, 132.9, 132.1, 130.3, 129.6, 
128.3, 126.2, 113.7, 111.5, 69.5, 64.8, 55.2, 53.3, 43.6, 43.3, 41.9, 38.5, 38.3, 36.7, 29.6, 27.5, 25.9, 22.7, 
19.2, 17.5; m/z (EI) 464 (M), 429 (M–Cl), 342 (M–BzOH), 307 (M–Cl–BzOH); HRMS (ESI): [M+Na]+, 
found 487.2011. C29H33ClO3Na requires 487.2010. Data for compound 11: δH (500 MHz, CDCl3) 8.05 (d, J = 
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7.8 Hz, 2H), 7.58 (t, J = 7.5 Hz, 1H), 7.46 (dd, J = 7.8, 7.8 Hz, 2H), 7.18 (d, J = 8.6 Hz, 1H), 6.71 (dd, J = 
8.6, 2.9 Hz, 1H), 6.62 (d, J = 2.6 Hz, 1H), 4.93 (dd, J = 7.2, 7.2 Hz, 1H), 4.29 (dd, J = 11.5, 7.8 Hz, 1H), 4.23 
(dd, J = 11.5, 6.1 Hz, 1H), 3.77 (s, 3H), 2.91–2.80 (m, 2H), 2.36–2.29 (m, 1H), 2.21–2.08 (m, 2H), 1.87–1.80 
(m, 1H), 1.72–1.64 (m, 2H), 1.55–1.48 (m, 3H), 1.41 (ddd, J = 11.8, 11.8, 4.0 Hz, 1H), 1.37–1.30 (m, 1H), 
1.14 (d, J = 6.3, 4.0 Hz, 1H), 1.10–1.04 (m, 1H), 1.01 (s, 3H), 0.68 (dd, J = 8.3, 6.9 Hz, 1H); δC (125 MHz, 
CDCl3) 166.0, 157.5, 137.8, 133.3, 132.7, 129.72, 129.68, 128.5, 126.1, 113.8, 111.4, 66.2, 60.4, 55.2, 45.9, 
44.3, 42.9, 39.0, 37.4, 35.0, 29.7, 27.9, 26.6, 26.3, 24.6, 17.7, 10.5; m/z (FAB) 464 (M), 429 (M–Cl), 307 
(M–Cl–BzOH); HRMS (ESI): [M+Na]+, found 487.2021. C29H33ClO3Na requires 487.2010. 
 
4.2.9. Synthesis of 
((2'S,8S,9S,13S,14S,17S)-3-methoxy-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydrospiro[cyclopenta[a]phen
anthrene-17,1'-cyclopropan]-2'-yl)methanol ((20S)-12). To a solution of compound (20S)-10 (2.09 g, 4.50 
mml) in toluene (23 mL) was added a 3.6 M Red-Al solution in toluene (6.3 mL, 23 mmol) under argon at 
0 °C. After being stirred at room temperature for 6 h, the reaction was quenched with saturated aqueous 
Rochell salt. The aqueous layer was extracted with EtOAc, and the combined organic layers were washed 
with brine, dried over Na2SO4, and concentrated under reduced pressure to give a yellow oil. The crude 
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material was purified by column chromatography (hexane/diethyl ether 7:3) to afford (20S)-12 (1.17 g, 79%) 
as a white solid; Found: C, 80.68; H, 9.54. C22H30O2 requires C, 80.94; H, 9.26%; Mp 112–113°C; [α]D20 
+27.1 (c 1.00, CHCl3); νmax (CHCl3) 3410 (br), 3009, 2932, 2866, 1609, 1501, 1450, 1219 cm–1; δH (500 
MHz, CDCl3) 7.19 (d, J = 8.6 Hz, 1H), 6.70 (dd, J = 8.6, 2.3 Hz, 1H), 6.63 (d, J = 2.3 Hz, 1H), 3.77 (s, 3H), 
3.64 (br m, 1H), 3.53 (br m, 1H), 2.91–2.82 (m, 2H), 2.28–2.18 (m, 2H), 2.10–2.03 (m, 1H), 1.94–1.87 (m, 
2H), 1.50–1.39 (m, 6H), 1.25–1.18 (m, 2H), 1.11 (ddd, J = 12.6, 12.6, 4.0 Hz, 1H), 0.99–0.92 (m, 2H), 0.81 
(s, 3H); δC (125 MHz, CDCl3) 157.4, 138.0, 132.8, 126.2, 113.7, 111.4, 65.1, 55.1, 53.3, 43.9, 41.4, 39.5, 
36.3, 33.2, 29.9, 29.0, 27.8, 26.1, 24.6, 19.8, 17.2, 16.2; m/z (EI) 326 (M), 308 (M–H2O). 
 
4.2.10. Synthesis of 
((2'R,8S,9S,13S,14S,17S)-3-methoxy-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydrospiro[cyclopenta[a]phen
anthrene-17,1'-cyclopropan]-2'-yl)methanol ((20R)-12). A mixture of (20R)-10 (1.59 g, 3.42 mmol), NaBH4 
(776 mg, 20.5 mmol) and DMSO (14 mL) was stirred for 20 h at 130 °C. After cooling to room temperature, 
water was added to the mixture. The aqueous layer was extracted with hexane/EtOAc (4:1), and the 
combined organic layers were washed with brine, dried over Na2SO4, and concentrated in vacuo. The residue 
was partially purified by column chromatography (hexane/diethyl ether 1:1) to give (20R)-12 (584 mg, 53%) 
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as a white gum; [α]D20 +19.6 (c 1.00, CHCl3); νmax (CHCl3) 3383 (br), 2928, 2862, 1609, 1574, 1501, 1454, 
1281, 1018 cm–1; δH (500 MHz, CDCl3) 7.19 (d, J = 8.6 Hz, 1H), 6.71 (dd, J = 8.3, 2.6 Hz, 1H), 6.63 (d, J = 
2.6 Hz, 1H), 3.87 (dd, J = 10.9, 6.3 Hz, 1H), 3.77 (s, 3H), 3.54 (dd, J = 10.9, 10.9 Hz, 1H), 2.93–2.78 (m, 
2H), 2.31–2.17 (m, 2H), 2.14–2.03 (m, 1H), 1.97–1.89 (m, 1H), 1.88–1.78 (m, 1H), 1.58–1.30 (m, 8H), 1.17–
1.11 (m, 1H), 0.89 (s, 3H), 0.67 (dd, J = 4.6, 4.6 Hz, 1H), 0.42 (dd, J = 8.3, 4.3 Hz, 1H); δC (125 MHz, 
CDCl3) 157.3, 137.9, 132.6, 126.2, 113.7, 111.4, 63.1, 55.1, 54.5, 43.5, 41.4, 39.1, 36.6, 35.8, 29.8, 27.6, 26.4, 
25.0, 24.6, 17.1 (two signals missing); m/z (EI) 326 (M); HRMS (ESI): [M+Na]+, found 349.2145. 
C22H30O2Na requires 349.2138. 
 
4.2.11. Synthesis of 
(2'S,8S,9S,13S,14S,17S)-3-methoxy-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydrospiro[cyclopenta[a]phen
anthrene-17,1'-cyclopropane]-2'-carbaldehyde ((20S)-13). To a solution of oxalyl chloride (0.32 mL, 3.7 
mmol) in CH2Cl2 (4.0 mL) was dropwise added a solution of DMSO (0.40 mL, 5.6 mmol) in CH2Cl2 (5.0 
mL) at –78 °C. After being stirred for 5 min, a solution of (20S)-12 (601 mg, 1.84 mmol) in CH2Cl2 (9.0 mL) 
was dropwise added. After being stirred for 10 min at –78 °C, triethylamine (1.5 ml, 10.8 mmol) was added. 
After being stirred for 20 min, the resulting mixture was allowed to warm to ambient temperature, diluted 
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with CHCl3, and quenched with saturated aqueous NH4Cl. The aqueous layer was extracted with CHCl3, and 
the combined organic layers were washed with brine, dried over Na2SO4, and concentrated under reduced 
pressure. The crude material was purified by column chromatography (hexane/EtOAc 10:1) to afford 
(20S)-13 (490 mg, 82%) as a white solid. Analytical sample was obtained by recrystallization from 
hexane/EtOAc as a white needle; Found C, 81.17; H, 8.55. C22H28O2 requires C, 81.44; H, 8.70%; Mp 148–
149 °C (dec.); [α]D20 +47.7 (c 1.00, CHCl3); νmax (CHCl3) 2932, 2913, 2866, 1701, 1609, 1501, 1238, 1172, 
1042 cm–1; δH (500 MHz, CDCl3) 9.12 (d, J = 6.3 Hz, 1H), 7.19 (d, J = 8.6 Hz, 1H), 6.71 (dd, J = 8.6, 2.6 Hz, 
1H), 6.63 (d, J = 2.3 Hz, 1H), 3.77 (s, 3H), 2.97–2.83 (m, 2H), 2.33–2.17 (m, 3H), 2.00–1.93 (m, 2H), 1.79–
1.70 (m, 2H), 1.52–1.39 (m, 6H), 1.26 (ddd, J = 12.1, 3.4, 3.4 Hz, 1H), 1.18–1.15 (m, 2H), 0.83 (s, 3H); δC 
(125 MHz, CDCl3) 201.8, 157.5, 137.9, 132.3, 126.2, 113.8, 111.4, 55.1, 52.4, 43.80, 43.78, 42.6, 39.3, 32.9, 
31.0, 29.8, 29.5, 27.7, 25.9, 24.7, 21.0, 17.1; m/z (EI) 324 (M), 309 (M–Me), 291 (M–Me–H2O). 
 
4.2.12. Synthesis of 
(2'R,8S,9S,13S,14S,17S)-3-methoxy-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydrospiro[cyclopenta[a]phen
anthrene-17,1'-cyclopropane]-2'-carbaldehyde ((20R)-13). To a solution of oxalyl chloride (0.37 mL, 4.3 
mmol) in CH2Cl2 (5.0 mL) was dropwise added a solution of DMSO (0.46 ml, 6.5 mmol) in CH2Cl2 (5.0 mL) 
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at –78 °C. After being stirred for 5 min, a solution of (20R)-12 (584 mg, 1.80 mmol) in CH2Cl2 (12 mL) was 
dropwise added. After being stirred for 20 min at –78 °C, triethylamine (1.8 mL, 13 mmol) was added. After 
being stirred for 10 min, the resulting mixture was allowed to warm to ambient temperature, diluted with 
CHCl3, and quenched with saturated aqueous NH4Cl. The aqueous layer was extracted with CHCl3, and the 
combined organic layers were washed with brine, dried over Na2SO4, and concentrated under reduced 
pressure. The crude material was purified by column chromatography (hexane/EtOAc 10:1) to afford 
(20R)-13 (471 mg, 81%) as a white solid; Found C, 81.50; H, 8.92. C22H28O2 requires C, 81.44; H, 8.70%; 
Mp 128–129 °C; [α]D20 +42.7 (c 1.00, CHCl3); νmax (CHCl3) 2932, 2866, 1694, 1609, 1501, 1161, 1038 cm–1; 
δH (500 MHz, CDCl3) 9.16 (d, J = 7.2 Hz, 1H), 7.19 (d, J = 8.6 Hz, 1H), 6.72 (dd, J = 8.5, 2.4 Hz, 1H), 6.64 
(d, J = 2.0 Hz, 1H), 3.78 (s, 3H), 2.93–2.83 (m, 2H), 2.37–2.15 (m, 3H), 1.95–1.85 (m, 3H), 1.75 (dd, J = 5.2, 
5.2  Hz, 1H), 1.62–1.37 (m, 8H), 1.10 (dd, J = 7.9, 5.0 Hz, 1H), 0.89 (s, 3H); δC (125 MHz, CDCl3) 200.4, 
157.5, 137.8, 132.2, 126.2, 113.8, 111.5, 55.2, 54.4, 44.9, 43.4, 42.0, 39.2, 36.3, 36.2, 35.4, 29.8, 27.5, 26.3, 
24.4, 21.9, 18.0; m/z (EI) 324 (M), 309 (M–Me), 291 (M–Me–H2O). 
 
4.2.13. Synthesis of 3-hydroxy-3-methylbutyl 4-methylbenzenesulfonate (14). To a stirred solution of 
3-methyl-1,3-butanediol (4.19 g, 40.2 mmol) in pyridine (100 mL) was added tosyl chloride (9.15 g, 48.0 
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mmol) at 0 °C. After being stirred for 12 h at room temperature, the reaction mixture was quenched with 
water. The aqueous layer was extracted with EtOAc. The combined organic layers were washed with 
saturated aqueous NaHCO3 and brine, dried over Na2SO4, concentrated in vacuo, and azeotroped with 
toluene. The resulting pale yellow oil was purified by column chromatography (hexane/EtOAc 3:2 to 1:1) to 
afford 14 (7.62 g, 73%) as a colorless oil; νmax (neat) 3518 (br), 2970, 1597, 1465, 1354, 1172 cm–1; δH (500 
MHz, CDCl3) 7.80 (d, J = 8.3 Hz, 2H), 7.35 (d, J = 8.1 Hz, 2H), 4.21 (t, J = 6.9 Hz, 2H), 2.45 (s, 3H), 1.86 (t, 
J = 6.9 Hz, 2H), 1.22 (s, 6H); δC (125 MHz, CDCl3) 144.7, 132.7, 129.7, 127.7, 69.3, 67.5, 41.5, 29.4, 21.4; 
m/z (FAB) 259 (M+H), 241 (M–OH).; HRMS (FAB): [M+H]+, found 259.0975. C12H19O4S requires 
259.0999. 
 
4.2.14. Synthesis of 2-((3-methyl-3-((triethylsilyl)oxy)butyl)sulfonyl)benzo[d]thiazole (15). To a solution of 
14 (7.62 g, 29.5 mmol) in acetone (98 mL) was added NaI (11.2 g, 74.7 mmol). The mixture was heated 
under reflux for 2 h. The resulting mixture was allowed to cool to room temperature, and concentrated in 
vacuo. The residue was dissolved in EtOAc, and washed with water. The aqueous layer was extracted with 
EtOAc, and the combined organic layers were washed with brine, dried over Na2SO4, and concentrated under 
reduced pressure to give a brown oil (5.79 g). To a solution of the brown oil (5.79 g) in THF (90 mL) were 
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added triethylamine (5.6 mL, 41 mmol) and 2-mercaptobenzothiazole (5.67 g, 33.9 mmol). After being 
heated under reflux for 12 h, the reaction mixture was allowed to cool to room temperature , diluted with 
EtOAc ,and washed with water. The aqueous layer was extracted with EtOAc, and the combined organic 
layers were washed with brine, and dried over Na2SO4. Concentration under reduced pressure gave a yellow 
oil (6.87 g). To a solution of the yellow oil (6.87 g) in CH2Cl2 (135 mL) was added mCPBA (75%, 18.8 g, 
81.7 mmol) at 0 °C. After being stirred for 6 h at room temperature, the reaction mixture was quenched with 
saturated aqueous NaHCO3. The organic layer was washed with brine, dried over Na2SO4, and concentrated 
in vacuo. The residue was dissolved in CHCl3, and passed through a short pad of silica gel with 
hexane/EtOAc (1:1) to give a white solid. (7.67 g). To a solution of the white solid (7.67 g) in CH2Cl2 (67 
mL) were added triethylamine (7.5 mL, 54 mmol) and triethylsilyl trifluoromethanesulfonate (7.3 mL, 32 
mmol) at 0 °C under argon. After being stirred for 7 h at room temperature, the reaction mixture was 
quenched with water. The aqueous layer was extracted with ether, and the combined organic layers were 
washed with brine, dried over Na2SO4, and concentrated in vacuo to give a brown solid. The residue was 
purified by column chromatography (hexane/EtOAc 10:1) to afford 15 (8.49 g, 72%, 4 steps) as a white 
solid; Found C, 53.90; H, 7.31; N, 3.47. C18H29NO3S2Si requires C, 54.10; H, 7.31; N, 3.50%; Mp 57–59 °C; 
νmax (neat) 2951, 2873, 1470, 1327, 1304, 1146 cm–1; δH (500 MHz, CDCl3) 8.23 (dd, J = 8.2, 1.4 Hz, 1H), 
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8.02 (dd, J = 8.1, 1.4 Hz, 1H), 7.65 (ddd, J = 8.2, 7.0, 1.4 Hz, 1H), 7.60 (ddd, J = 7.8, 6.6, 1.5 Hz, 1H), 3.65–
3.62 (m, 2H), 1.95–1.92 (m, 2H), 1.23 (s, 6H), 0.87 (t, J = 8.0 Hz, 9H), 0.51 (q, J = 8.0 Hz, 6H); δC (125 
MHz, CDCl3) 65.6, 152.7, 136.7, 127.9, 127.5, 125.4, 122.2, 71.8, 51.2, 36.9, 29.7, 6.9, 6.5; m/z (FAB) 400 
(M+H), 370 (M–Et), 268 (M–TES). 
 
4.2.15. Synthesis of 
triethyl(((E)-5-((2'R,8S,9S,13S,14S,17S)-3-methoxy-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydrospiro[cyc
lopenta[a]phenanthrene-17,1'-cyclopropan]-2'-yl)-2-methylpent-4-en-2-yl)oxy)silane ((20S)-16). To a 
solution of 15 (352 mg, 1.08 mmol) in THF (6.0 mL) was added a 1.0 M solution of LiHMDS in toluene (1.6 
mL, 1.6 mmol) at –78 °C under argon. After being stirred for 30 min, a solution of (20S)-13 (352 mg, 1.08 
mmol) in THF (10 mL) was added, and stirred for 1 h. The reaction mixture was diluted with EtOAc, and 
quenched with saturated aqueous NH4Cl. The aqueous layer was extracted with EtOAc, and the combined 
organic layers were washed with brine, dried over Na2SO4, and concentrated in vacuo to give a yellow oil. 
The crude material was purified by column chromatography (hexane/diethyl ether 50:1) to afford an 
inseparable E/Z mixture of (20S)-16 (470 mg, 86%, E/Z 9:1) as a colorless oil. The following data were 
collected as a 9:1 E/Z mixture; [α]D20 +23.3 (c 1.00, CHCl3); νmax (neat) 2954, 2909, 2874, 1609, 1501, 1238, 
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1042, 1018 cm–1; δH (500 MHz, CDCl3) 7.20 (d, J = 8.6 Hz, 1H), 6.70 (dd, J = 8.6, 2.6 Hz, 1H), 6.63 (d, J = 
2.0 Hz, 1H), 5.52 (dt, J = 15.2, 7.5 Hz, 0.9H), 5.50 (dt, J = 10.9, 3.7 Hz, 0.1H), 5.08 (dd, J = 15.2, 8.9 Hz, 
0.9H), 5.01 (dd, J = 10.3, 10.3 Hz, 0.1H), 3.77 (s, 3H), 2.95–2.75 (m, 2H), 2.34–2.02 (m, 5H), 1.97–1.84 (m, 
2H), 1.50–1.28 (m, 7H), 1.27–1.18 (m, 1.6H), 1.18 (s, 2.7H), 1.17 (s, 2.7H), 1.15–1.05 (m, 2H), 0.95 (t, J = 
8.1 Hz, 9H), 0.78 (s, 3H), 0.57 (q, J = 8.0 Hz, 6H), 0.15 (dd, J = 5.5, 5.5 Hz, 1H); δC (125 MHz, CDCl3) 
157.4, 138.1, 134.3, 132.9, 126.3, 125.5, 113.8, 111.4, 73.5, 55.2, 53.5, 48.4, 43.9, 41.9, 39.4, 38.0, 33.4, 29.9, 
29.7, 29.6, 27.8, 26.1, 24.7, 20.9, 19.2, 16.7, 7.1, 6.8 (Signals of the minor isomer were not observed); m/z 
(EI) 508 (M), 493 (M–Me), 479 (M–Et), 450 (M–2Et). 376 (M–TESOH); HRMS (ESI): [M+Na]+, found 
531.3631. C33H52O2SiNa requires 531.3629. 
 
4.2.16. Synthesis of 
triethyl(((E)-5-((2'S,8S,9S,13S,14S,17S)-3-methoxy-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydrospiro[cycl
openta[a]phenanthrene-17,1'-cyclopropan]-2'-yl)-2-methylpent-4-en-2-yl)oxy)silane ((20R)-16). To a 
solution of 15 (747 mg, 1.87 mmol) in THF (5 mL) was added a 1.0 M solution of LiHMDS in toluene (1.9 
mL, 1.9 mmol) at –78 °C under argon. After being stirred for 30 min, a solution of (20R)-13 (463 mg, 1.43 
mmol) in THF (10 mL) was added, and stirred for 1 h. The reaction mixture was diluted with EtOAc, and 
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quenched with saturated aqueous NH4Cl. The aqueous layer was extracted with EtOAc, and the combined 
organic layers were washed with brine, dried over Na2SO4, and concentrated in vacuo to give a yellow oil. 
The crude material was purified by column chromatography (hexane/diethyl ether 50:1) to afford an 
inseparable E/Z mixture of (20R)-16 (667 mg, 92%, E/Z 4:1) as a colorless oil. The following data were 
collected as a 4:1 E/Z mixture; [α]D20 +28.6 (c 1.00, CHCl3); νmax (CHCl3) 2932, 2913, 2874, 1609, 1501, 
1458, 1234, 1153, 1038, 1015 cm–1; δH (500 MHz, CDCl3) 7.20 (d, J = 8.6 Hz, 1H), 6.71 (dd, J = 8.3, 2.3 Hz, 
1H), 6.63 (d, J = 2.3 Hz, 1H), 5.54 (dt, J = 15.2, 7.2 Hz, 0.8H), 5.43 (dt, J = 10.4, 7.8 Hz, 0.2H), 5.29–5.18 
(m, 1H), 3.77 (s, 3H), 2.92–2.79 (m, 2H), 2.33–2.05 (m, 5H), 1.95–1.78 (m, 2H), 1.60–1.26 (m, 9H), 1.22 (s, 
1.2H), 1.18 (s, 4.8H), 0.95 (t, J = 8.0 Hz, 9H), 0.88 (s, 2.4H), 0.87 (s, 0.6H), 0.83–0.78 (m, 1H), 0.57 (q, J = 
8.0 Hz, 6H), 0.54–0.51 (m, 1H); δC (125 MHz, CDCl3) 57.4, 138.0, 133.3, 132.9, 126.3, 125.5, 113.7, 111.4, 
73.7, 55.2, 54.6, 48.6, 43.6, 41.7, 39.1, 37.9, 36.2, 35.7, 29.9, 29.8, 29.5, 27.7, 26.4, 25.7, 24.8, 20.3, 16.0, 
7.1, 6.8 (Signals of the minor isomer were not observed); m/z (EI) 508 (M), 493 (M–Me), 479 (M–Et), 450 
(M–2Et). 376 (M–TESOH); HRMS (ESI): [M+Na]+, found 531.3619. C33H52O2SiNa requires 531.3629. 
 
4.2.17. Synthesis of 
5-((2'S,8S,9S,13S,14S,17S)-3-methoxy-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydrospiro[cyclopenta[a]ph
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enanthrene-17,1'-cyclopropan]-2'-yl)-2-methylpentan-2-ol ((20S)-17). To a suspension of (20S)-16 (166 mg, 
0.326 mmol, E/Z 9:1) and dipotassium azodicarboxylate (317 mg, 1.63 mmol) in CH2Cl2 (1.0 mL) was added 
a 1 M solution of acetic acid in CH2Cl2 (3.3 mL, 3.3 mmol) dropwise at reflux. Additional dipotassium 
azodicarboxylate (317 mg, 1.63 mmol) and a 1.0 M solution of acetic acid (3.3 mL, 3.3 mmol) were added 
after 3, 6, 22, 25, 28, 31, 34, 43 h, respectively. The reaction mixture was stirred under reflux for a total 46 h, 
and the resulting mixture was filtered through Celite. The eluent was concentrated under reduced pressure to 
give the spirocyclopropane (166 mg) as a pale yellow oil. To a solution of the spirocyclopropane (166 mg) in 
THF (2 mL) was added a 1.0 M solution of TBAF (1.7 mL, 1.7 mmol), and the solution was heated under 
reflux for 6 h. After cooling to room temperature, the resulting mixture was diluted with EtOAc, and washed 
with water. The aqueous layer was extracted with EtOAc, dried over Na2SO4, and concentrated in vacuo to 
give a yellow oil. The crude material was purified by column chromatography (hexane/EtOAc 4:1) to give 
(20S)-17 (92.3 mg, 71% for 2 steps) as a white solid; Mp 107–109 °C; [α]D20 +21.1 (c 1.00, CHCl3); νmax 
(CHCl3) 3333 (br), 2970, 2924, 2901, 1501, 1454, 1381, 1084, 1049 cm–1; δH (500 MHz, CDCl3) 7.20 (d, J = 
8.6 Hz, 1H), 6.70 (dd, J = 8.5, 2.4 Hz, 1H), 6.63 (d, J = 2.0 Hz, 1H), 3.77 (s, 3H), 2.92–2.82 (m, 2H), 2.27–
2.18 (m, 2H), 2.04–2.01 (m, 1H), 1.95–1.87 (m, 2H), 1.54–1.16 (m, 20H), 1.10 (ddd, J = 13.2, 13.2, 4.0 Hz, 
1H), 0.85 (dd, J = 8.9, 4.3 Hz, 1H), 0.77 (s, 3H), 0.58–0.52 (m, 1H), –0.26 (dd, J = 4.9, 4.9 Hz, 1H); δC (125 
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MHz, CDCl3) 157.3, 138.0, 132.9, 126.2, 113.7, 111.3, 70.9, 55.1, 53.6, 43.9, 43.8, 41.3, 39.4, 36.0, 33.3, 
31.6, 29.9, 29.2, 29.1, 29.0, 27.8, 26.1, 24.9, 24.6, 17.4, 17.1, 17.0; m/z (EI) 396 (M), 378 (M–H2O), 363 (M–
H2O–Me); HRMS (ESI): [M+H]+, found 397.3096. C27H41O2 requires 397.3101.  
 
4.2.18. Synthesis of 
5-((2'R,8S,9S,13S,14S,17S)-3-methoxy-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydrospiro[cyclopenta[a]ph
enanthrene-17,1'-cyclopropan]-2'-yl)-2-methylpentan-2-ol ((20R)-17). To a suspension of (20R)-16 (483 mg, 
0.949 mmol, E/Z 4:1) and dipotassium azodicarboxylate (922 mg, 4.75 mmol) in CH2Cl2 (5.0 mL) was added 
a 1.0 M solution of acetic acid in CH2Cl2 (9.4 mL, 9.4 mmol) dropwise at reflux. Additional dipotassium 
azodicarboxylate (922 mg, 4.75 mmol) and a 1.0 M solution of acetic acid in CH2Cl2 (9.4 mL, 9.4 mmol) 
were added after 3, 17, 29, 42, 47, 53, 67, 70, 74, 77 h, respectively. The reaction mixture was stirred under 
reflux for a total 89 h, and the resulting mixture was filtered through Celite. The eluent was concentrated 
under reduced pressure to give a pale yellow oil (402 mg, only about 50% conversion by 1H NMR). Again, to 
a suspension of the pale yellow oil (402 mg) and dipotassium azodicarboxylate (768 mg, 3.95 mmol) in 
CH2Cl2 (4.0 mL) was added a 1.0 M solution of acetic acid in CH2Cl2 (8.0 mL, 8.0 mmol) dropwise at reflux. 
Additional dipotassium carboxylate (770 mg, 3.96 mmol) and a 1.0 M solution of acetic acid in CH2Cl2 (8.0 
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ml, 8.0 mmol) were added after 5, 9, 12, 32, 36, 49, 58 h, respectively. The reaction mixture was stirred under 
reflux for a total 72 h, and the resulting white suspension was allowed to cool to room temperature, and 
diluted with water. The aqueous layer was extracted with CHCl3, and washed with brine, dried over Na2SO4. 
Concentration under reduced pressure gave a pale yellow oil (390 mg). To a solution of the pale yellow oil 
(390 mg, 0.763 mmol) in THF (5.0 mL) was added a 1.0 M solution of TBAF in THF (2.3 mL, 2.3 mmol). 
After being refluxed for 13 h, the resulting mixture was allowed to cool to room temperature, and diluted 
with water. The aqueous layer was extracted with EtOAc twice. The combined organic layers were washed 
with brine, dried over Na2SO4, concentrated under reduced pressure to give a yellow oil. The residue was 
purified by column chromatography (hexane/EtOAc 5:1) to afford (20R)-17 (284 mg, 75% for 2 steps) as a 
white solid. Mp 95–96 °C; [α]D20 +13.0 (c 1.00, CHCl3); νmax (CHCl3) 3333 (br), 2970, 2924, 2901, 1501, 
1454, 1381, 1084, 1049 cm–1; δH (500 MHz, CDCl3) 7.19 (d, J = 8.6 Hz, 1H), 6.71 (dd, J = 8.6, 2.6 Hz, 1H), 
6.63 (d, J = 2.6 Hz, 1H), 3.77 (s, 3H), 2.92–2.80 (m, 2H), 2.29–2.16 (m, 2H), 2.04–1.98 (m, 1H), 1.94–1.89 
(m, 1H), 1.84–1.73 (m, 2H), 1.56–1.24 (m, 13H), 1.22 (s, 6H), 1.13–1.05 (m, 1H), 0.91 (s, 3H), 0.72 (m, 1H), 
0.42 (dd, J = 4.9, 4.9, Hz, 1H), 0.27 (dd, J = 8.6, 4.0 Hz, 1H); δC (125 MHz, CDCl3) 157.4, 138.1, 132.9, 
126.2, 113.7, 111.4, 71.1, 55.2, 54.7, 43.9, 43.7, 41.6, 39.1, 36.7, 36.2, 35.6, 29.92, 29.90, 29.3, 29.2, 27.7, 
26.5, 25.4, 24.8, 22.6, 18.4, 16.2; m/z (EI) 396 (M), 378 (M–H2O), 363 (M–H2O–Me), 348 (M–H2O–2Me); 
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HRMS (ESI): [M+H]+, found 397.3115. C27H41O2 requires 397.3101.  
 
4.2.19. Synthesis of 
(2'S,8S,9S,13S,14S,17S)-2'-(4-hydroxy-4-methylpentyl)-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydrospiro[
cyclopenta[a]phenanthrene-17,1'-cyclopropan]-3-ol ((20S)-18). To a solution of diphenylphosphine (0.12 
mL, 0.69 mmol) in THF (1.0 mL) were added a 2.5 M solution of n-BuLi in hexane (0.27 mL, 0.68 mmol) 
and a solution of (20S)-17 (52.0 mg, 0.132 mmol) in THF (1.0 mL). After the red solution was heated under 
reflux for 25 h, the resulting mixture was allowed to cool to room temperature. The mixture was diluted with 
EtOAc, washed with 10% HCl, saturated aqueous NaHCO3 and brine, and dried over Na2SO4. Concentration 
under reduced pressure gave a pale yellow oil, which was purified by column chromatography 
(hexane/EtOAc 7:3) to give (20S)-18 (38.2 mg, 76%) as a white solid; Mp 80–83 °C; [α]D20 +9.85 (c 0.50, 
CHCl3); νmax (KBr) 3717 (br), 3292 (br), 2968, 2932, 2864, 1611, 1585, 1501, 1452, 1375, 1287, 1240 cm–1; 
δH (500 MHz, CDCl3) 7.15 (d, J = 8.6 Hz, 1H), 6.62 (dd, J = 8.3, 2.6 Hz, 1H), 6.56 (d, J = 2.3 Hz, 1H), 4.71 
(br s, 1H), 2.90–2.77 (m, 2H), 2.30–2.13 (m, 2H), 2.09–1.99 (m, 1H), 1.97–1.83 (m, 2H), 1.55–1.21 (m, 
19H), 1.16 (ddd, J = 12.3, 2.9, 2.9 Hz, 1H), 1.08 (ddd, J = 12.6, 12.6, 4.0 Hz, 1H), 0.85 (dd, J = 9.2, 4.3 Hz, 
1H), 0.76 (s, 3H), 0.58–0.51 (m, 1H), –0.26 (dd, J = 4.9, 4.9 Hz, 1H); δC (125 MHz, CDCl3) 153.4, 138.4, 
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132.9, 126.4, 115.2, 112.6, 71.5, 53.7, 44.0, 43.8, 41.4, 39.5, 36.0, 33.3, 31.6, 29.7, 29.2, 29.1, 29.0, 27.8, 
26.2, 24.9, 24.6, 17.5, 17.11, 17.07; m/z (EI) 382 (M), 364 (M–H2O), 349 (M–H2O–Me); HRMS (ESI): 
[M+H]+, found 383.2931. C26H39O2 requires 383.2945.  
 
4.2.20. Synthesis of 
(2'R,8S,9S,13S,14S,17S)-2'-(4-hydroxy-4-methylpentyl)-13-methyl-6,7,8,9,11,12,13,14,15,16-decahydrospiro[
cyclopenta[a]phenanthrene-17,1'-cyclopropan]-3-ol ((20R)-18). To a solution of diphenylphosphine (0.33 ml, 
1.90 mmol) in THF (1 ml) were added a 2.5 M solution of n-BuLi in hexane (0.76 ml, 1.90 mmol) and a 
solution of (20R)-17 (151 mg, 0.381 mmol) in THF (3 ml). After the red solution was heated under reflux for 
21 h, the resulting mixture was allowed to cool to room temperature. The mixture was diluted with EtOAc, 
washed with 10% HCl, saturated aqueous NaHCO3 and brine, and dried over Na2SO4. Concentration under 
reduced pressure gave a pale yellow oil, which was purified by column chromatography (hexane/EtOAc 4:1 
to 7:3) to give (20R)-18 (133 mg, 91%) as a white solid; Mp 192–193 °C; [α]D20 +14.1 (c 1.00, THF); νmax 
(KBr) 3319 (br), 2968, 2857, 2816, 1614, 1585, 1504, 1440, 1375, 1283, 1213, 1148, 895 cm–1; δH (500 MHz, 
CDCl3) 7.14 (d, J = 8.3 Hz, 1H), 6.62 (dd, J = 8.3, 2.0 Hz, 1H), 6.56 (d, J = 2.3 Hz, 1H), 2.88–2.78 (m, 2H), 
2.26–2.15 (m, 2H), 2.05–1.98 (m, 1H), 1.93–1.87 (m, 1H), 1.84–1.73 (m, 2H), 1.56–1.29 (m, 14H), 1.23 (s, 
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6H), 1.10–1.05 (m, 1H), 0.91 (s, 3H), 0.72 (m, 1H), 0.42 (dd, J = 4.3, 4.3, Hz, 1H), 0.27 (dd, J = 8.6, 4.0 Hz, 
1H); δC (125 MHz, acetone-d6) 156.5, 139.0, 132.7, 127.5, 116.5, 114.1, 70.7, 56.2, 45.4, 45.2, 43.0, 40.9, 
38.2, 37.5, 37.0, 31.5, 31.0, 30.4, 29.1, 27.9, 26.8, 26.0, 24.1, 19.5, 17.3; m/z (EI) 382 (M), 364 (M–H2O), 
349 (M–H2O–Me); HRMS (ESI): [M+Na]+, found 405.2772. C26H38O2Na requires 405.2764.  
 
4.2.21. Synthesis of 
tert-butyl(((6bS,8aS,8bR,9S,10aS,11aS,11bR)-4-methoxy-8a-methyl-9-((E)-4-methyl-4-((triethylsilyl)oxy)pent
-1-en-1-yl)-1,2,6b,7,8,8a,9,10,10a,11,11a,11b-dodecahydro-8bH-cyclobuta[3,4]cyclopenta[1,2-a]phenanthre
n-8b-yl)oxy)dimethylsilane (trans-19). To a solution of oxalyl chloride (0.38 mL, 4.4 mmol) in CH2Cl2 (5.0 
mL) was dropwise added a solution of DMSO (0.47 mL, 6.6 mmol) in CH2Cl2 (6.0 mL) at –78 °C. After 
being stirred for 5 min, trans-7 (1.00 g, 2.19 mmol) in CH2Cl2 (11 mL) was dropwise added. After being 
stirred for 40 min at –78 °C, triethylamine (1.8 mL, 13 mmol) was added. After being stirred for 20 min, the 
resulting mixture was allowed to warm to ambient temperature, diluted with CHCl3, and quenched with 
saturated aqueous NH4Cl. The aqueous layer was extracted with CHCl3, and the combined organic layers 
were washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was 
dissolved in CHCl3 and passed through a short pad of silica gel with hexane/diethyl ether (10:1) to obtain a 
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crude aldehyde (936 mg) as a white solid, which was used directly in the next step without further 
purification. To a solution of 15 (1.07 g, 2.69 mmol) in THF (7 mL) was added a 1.0 M solution of LiHMDS 
in toluene (2.7 mL, 2.7 mmol) at –78 °C under argon. After being stirred for 30 min, a solution of the above 
crude aldehyde (936 mg, 2.06 mmol) in THF (13 mL) was added, and stirred for 1 h. The reaction mixture 
was diluted with EtOAc, and quenched with saturated aqueous NH4Cl. The aqueous layer was extracted with 
EtOAc, and the combined organic layers were washed with brine, dried over Na2SO4, and concentrated in 
vacuo to give a yellow solid. The crude material was purified by column chromatography (hexane/diethyl 
ether 50:1) to afford an inseparable E/Z mixture of trans-19 (1.18 g, 84% for 2 steps, E/Z 3:2) as a colorless 
oil. The following data were collected as a 3:2 E/Z mixture; [α]D20 +11.5 (c 1.00, CHCl3); νmax (CHCl3) 2955, 
2928, 1501, 1458, 1254, 1238, 1045 cm–1; δH (500 MHz, CDCl3) 7.22 (d, J = 8.6 Hz, 0.4H), 7.21 (d, J = 8.6 
Hz, 0.6H), 6.71 (dd, J = 8.6, 2.9 Hz, 1H), 6.63 (d, J = 2.9 Hz, 1H), 5.86–5.77 (m, 1H), 5.49 (ddt, J = 10.9, 7.5, 
0.9 Hz, 0.4H), 5.43 (ddt, J = 15.5, 7.2, 1.4 Hz, 0.6H), 3.77 (s, 3H), 3.44–3.36 (m, 0.4H), 3.26–3.18 (m, 0.6H), 
2.93–2.81 (m, 2H), 2.60–2.54 (m, 0.4H), 2.51–2.42 (m, 1H), 2.38–2.28 (m, 1H), 2.27–2.13 (m, 4H), 2.06 
(ddd, J = 3.8, 3.8, 3.2 Hz, 0.6H), 1.97–1.90 (m, 1H), 1.89–1.78 (m, 1H), 1.60–1.33 (m, 6H), 1.20 (s, 1.2H), 
1.18 (s, 1.2H), 1.17 (s, 3.6H), 1.08–0.89 (m, 19H), 0.70 (s, 1.8H), 0.69 (s, 1.2H), 0.57 (q, J = 8.1 Hz, 2.4H), 
0.56 (q, J = 8.0 Hz, 3.6H), 0.27 (s, 1.2H), 0.21 (s, 1.8H), 0.133 (s, 1.8H), 0.127 (s, 1.2H); δC (125 MHz, 
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CDCl3) 157.4, 157.3, 138.1, 138.0, 133.02, 133.0, 132.7, 132.6, 127.0, 126.5, 126.4, 125.6, 113.7, 111.41, 
111.38, 92.0, 91.7, 73.6, 73.4, 55.2, 50.5, 48.47, 48.45, 48.3, 47.1, 47.0, 45.8, 44.0, 43.8, 43.3, 41.5, 41.0, 
38.87, 38.85, 33.7, 33.6, 31.2, 30.0, 29.94, 29.91, 29.85, 29.7, 28.7, 27.89, 27.85, 26.42, 26.37, 26.0, 25.9, 
25.8, 18.3, 17.01, 16.95, 7.1, 6.8, –2.4, –2.7, –3.1, –3.3 (some signals missing); m/z (EI) 638 (M), 623 (M–
Me), 609 (M–Et), 581 (M–tBu), 506 (M–TESOH); HRMS (ESI): [M+Na]+, found 661.4428. C39H66O3Si2Na 
requires 661.4442.  
 
4.2.22. Synthesis of 
tert-butyl(((6bS,8aS,8bR,9R,10aS,11aS,11bR)-4-methoxy-8a-methyl-9-((E)-4-methyl-4-((triethylsilyl)oxy)pent
-1-en-1-yl)-1,2,6b,7,8,8a,9,10,10a,11,11a,11b-dodecahydro-8bH-cyclobuta[3,4]cyclopenta[1,2-a]phenanthre
n-8b-yl)oxy)dimethylsilane (cis-19). To a solution of oxalyl chloride (0.49 mL, 5.7 mmol) in CH2Cl2 (7.0 mL) 
was dropwise added a solution of DMSO (0.61 mL, 8.6 mmol) in CH2Cl2 (6.0 mL) at –78 °C. After being 
stirred for 5 min, a solution of cis-7 (1.30 g, 2.85 mmol) in CH2Cl2 (15 mL) was dropwise added. After being 
stirred for 40 min at –78 °C, triethylamine (2.4 mL, 17 mmol) was added. After being stirred for 20 min, the 
resulting mixture was allowed to warm to ambient temperature, diluted with CHCl3, and quenched with 
saturated aqueous NH4Cl. The aqueous layer was extracted with CHCl3, and the combined organic layers 
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were washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was 
dissolved in CHCl3 and passed through a short pad of silica gel with hexane/EtOAc (20:1) to obtain a crude 
aldehyde (1.21 g) as a white solid, which was used directly in the next step without further purification. To a 
solution of 15 (1.39 g, 3.48 mmol) in THF (8.0 mL) was added a 1.0 M solution of LiHMDS in toluene (3.5 
mL, 3.5 mmol) at –78 °C under argon. After being stirred for 30 min, a solution of the above crude aldehyde 
(1.21 g, 2.66 mmol) in THF (19 mL) was added, and stirred for 1 h. The reaction mixture was diluted with 
EtOAc, and quenched with saturated aqueous NH4Cl. The aqueous layer was extracted with EtOAc, and the 
combined organic layers were washed with brine, dried over Na2SO4, and concentrated in vacuo to give a 
yellow oil. The crude material was purified by column chromatography (hexane/EtOAc 50:1) to afford an 
inseparable E/Z mixture of cis-19 (1.29 g, 71% for 2 steps, E/Z 1:1) as a colorless oil. The following data 
were collected as a 1:1 E/Z mixture; [α]D20 +4.95 (c 1.00, CHCl3); νmax (CHCl3) 2951, 2928, 2878, 2855, 
1501, 1462, 1234, 1153, 1099, 1045, 1018 cm–1; δH (500 MHz, CDCl3) 7.23 (d, J = 8.9 Hz, 1H), 6.72 (dd, J = 
8.6, 2.3 Hz, 1H), 6.64 (d, J = 2.3 Hz, 1H), 5.74 (dt, J = 10.0, 7.9 Hz, 0.5H), 5.43 (dd, J = 15.5, 6.1 Hz, 0.5H), 
5.45–5.32 (m, 1H), 3.78 (s, 3H), 3.27–3.21 (m, 0.5H), 3.11–3.04 (m, 0.5H), 2.96–2.82 (m, 2H), 2.60 (dd, J = 
7.5, 7.5 Hz, 0.5H), 2.54 (dd, J = 8.0, 8.0 Hz, 0.5H), 2.35–2.05 (m, 5H), 1.99–1.90 (m, 1H), 1.74–1.64 (m, 
1H), 1.62–1.38 (m, 8H), 1.20 (s, 1.5H), 1.19 (s, 1.5H), 1.18 (s, 1.5H), 1.16 (s, 1.5H), 0.95 (t, J = 8.0 Hz, 9H), 
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0.92 (s, 4.5H), 0.90 (s, 4.5H), 0.70 (s, 1.5H), 0.69 (s, 1.5H), 0.574 (q, J = 7.7 Hz, 3H), 0.569 (q, J = 8.1 Hz, 
3H), 0.26 (s, 1.5H), 0.22 (s, 1.5H), 0.10 (s, 1.5H), 0.08 (s, 1.5H); δC (125 MHz, CDCl3) 157.4, 137.9,134.1, 
132.90, 132.87, 132.8, 126.3, 126.1, 125.3, 113.8, 111.4, 90.7, 90.5, 73.6, 73.5, 55.1, 48.4, 48.34, 48.32, 47.0, 
46.9, 44.31, 44.27, 43.4, 40.8, 40.5, 40.3, 38.7, 38.6, 35.9, 32.1, 31.9, 30.4, 30.0, 29.9, 29.80, 29.76, 29.6, 
29.5, 29.3, 28.3, 27.8, 26.14, 26.10, 18.64, 18.56, 14.6, 14.5, 7.11, 6.8, –1.46, –1.51, –2.4 ppm (some signals 
missing); m/z (EI) 638 (M), 609 (M–Et), 581 (M–tBu), 506 (M–TESOH); HRMS (ESI): [M+Na]+, found 
661.4439. C39H66O3Si2Na requires 661.4442.  
 
4.2.23. Synthesis of 
5-((6bS,8aS,8bS,9R,10aS,11aS,11bR)-8b-((tert-butyldimethylsilyl)oxy)-4-methoxy-8a-methyl-2,6b,7,8,8a,8b,9
,10,10a,11,11a,11b-dodecahydro-1H-cyclobuta[3,4]cyclopenta[1,2-a]phenanthren-9-yl)-2-methylpentan-2-ol 
(trans-20). A mixture of trans-19 (1.18 g, 1.85 mmol, E/Z 3:2), 10% Pd/C (200 mg) and EtOAc/MeOH (1:1, 
18 mL) was stirred under H2 (1 atm) at room temperature for 10 h. The reaction mixture was filtered through 
Celite, and concentrated under reduced pressure to give a pale yellow oil, which was purified by column 
chromatography (hexane/diethyl ether 3:2) to afford trans-20 (626 mg, 64%) as a white solid; Mp 52–55 °C; 
[α]D20 +9.64 (c 1.00, CHCl3); νmax (CHCl3) 3422 (br), 2940, 2862, 1612, 1485, 1454, 1238, 1211, 1103 cm–1; 
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δH (500 MHz, CDCl3) 7.22 (d, J = 8.6 Hz, 1H), 6.71 (dd, J = 8.6, 2.6 Hz, 1H), 6.67 (d, J = 2.3 Hz, 1H), 3.78 
(s, 3H), 2.90–2.82 (m, 2H), 2.59 (dddd, J = 12.6, 12.6, 8.0, 5.5 Hz, 1H), 2.48–2.44 (m, 1H), 2.36–2.22 (m, 
3H), 1.95–1.88 (m, 2H), 1.84–1.72 (m, 2H), 1.68–1.64 (m, 2H), 1.56–1.38 (m, 7H), 1.36–1.28 (m, 1H), 1.21 
(s, 6H), 1.16–1.09 (m, 1H), 0.89 (s, 9H), 0.82 (ddd, J = 12.9, 8.6, 4.9 Hz, 1H), 0.72 (s, 3H), 0.18 (s, 3H), 0.11 
(s, 3H); δC (125 MHz, CDCl3) 157.3, 138.1, 132.9, 126.4, 113.7, 111.4, 90.4, 71.0, 55.2, 48.8, 48.6, 47.5, 
44.0, 43.9, 41.5, 39.0, 33.3, 31.9, 31.4, 30.0, 29.3, 29.2, 27.9, 27.4, 26.5, 25.9, 23.1, 18.3, 17.5, –2.7, –3.0; 
m/z (EI) 526 (M), 511 (M–Me), 411 (M–TBS); HRMS (ESI): [M+Na]+, found 549.3752. C33H54O3SiNa 
requires 549.3734. 
 
4.2.24. Synthesis of 
5-((6bS,8aS,8bS,9S,10aS,11aS,11bR)-8b-((tert-butyldimethylsilyl)oxy)-4-methoxy-8a-methyl-2,6b,7,8,8a,8b,9
,10,10a,11,11a,11b-dodecahydro-1H-cyclobuta[3,4]cyclopenta[1,2-a]phenanthren-9-yl)-2-methylpentan-2-ol 
(cis-20). A mixture of cis-19 (1.29 g, 2.02 mmol, E/Z 1:1), 10% Pd/C (215 mg) and EtOAc/MeOH (1:1, 20 
mL) was stirred under H2 (1 atm) at room temperature for 10 h. The reaction mixture was filtered through 
Celite, and concentrated under reduced pressure to give a white gum, which was purified by column 
chromatography (hexane/diethyl ether 3:2) to afford cis-20 (847 mg, 80%) as a white solid; Mp 63–66 °C; 
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[α]D20 +19.0 (c 1.00, CHCl3); νmax (neat) 3325 (br), 2970, 2928, 1612, 1500, 1254, 1092, 1045 cm–1; δH (500 
MHz, CDCl3) 7.22 (d, J = 8.6 Hz, 1H), 6.72 (dd, J = 8.6, 2.6 Hz, 1H), 6.64 (d, J = 2.6 Hz, 1H), 3.78 (s, 3H), 
2.89–2.83 (m, 2H), 2.54 (dd, J = 7.5, 7.5 Hz, 1H), 2.38–2.30 (m, 2H), 2.23 (dd, J = 9.9, 9.9 Hz, 1H), 1.93–
1.83 (m, 2H), 1.68–1.21 (m, 15H), 1.20 (s, 6H), 0.91 (s, 9H), 0.69 (s, 3H), 0.24 (s, 3H), 0.11 (s, 3H); δC (125 
MHz, CDCl3) 157.4, 138.0, 132.9, 126.4, 113.8, 111.4, 90.2, 71.1, 55.2, 48.3, 46.6, 44.4, 44.3, 40.0, 38.6, 
38.1, 32.0, 31.9, 29.9, 29.7, 29.5, 29.2, 29.0, 27.8, 26.2, 23.0, 18.6, 14.6, –1.2, –2.3; m/z (EI) 526 (M), 511 
(M–Me), 411 (M–TBS); HRMS (ESI): [M+Na]+, found 549.3737. C33H54O3SiNa requires 549.3734. 
 
4.2.25. Synthesis of 
(6bS,8aS,8bS,9R,10aS,11aS,11bR)-8b-((tert-butyldimethylsilyl)oxy)-9-(4-hydroxy-4-methylpentyl)-8a-methyl-
2,6b,7,8,8a,8b,9,10,10a,11,11a,11b-dodecahydro-1H-cyclobuta[3,4]cyclopenta[1,2-a]phenanthren-4-ol 
(trans-21). To a solution of diphenylphosphine (0.53 ml, 3.1 mmol) in THF (4.0 mL) were added a 2.5 M 
solution of n-BuLi in hexane (1.2 mL, 3.0 mmol) and a solution of trans-20 (533 mg, 1.01 mmol) in THF 
(6.0 mL). The red solution was heated under reflux for 27 h, and the diphenyl phosphine (0.35 mL, 2.0 
mmol) and a 2.5 M solution of n-BuLi in hexane (0.81 mL, 2.0 mmol) were added again to the mixture. After 
being stirred for additional 19 h under reflux, the resulting mixture was allowed to cool to room temperature. 
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The mixture was diluted with EtOAc, washed with 10% HCl, saturated aqueous NaHCO3 and brine, and 
dried over Na2SO4. Concentration under reduced pressure gave a pale yellow oil, which was purified by 
column chromatography (hexane/EtOAc 3:1) to give trans-21 (458 mg, 88%) as a white solid. Analytical 
sample was obtained by recrystallization from EtOAc as a white powder; Found 74.70; H, 10.29. C32H52O3Si 
requires C, 74.94; H, 10.22%; Mp 178–179 °C; [α]D20 +5.35 (c 1.00, CHCl3); νmax (neat) 3329 (br), 2974, 
2928, 2893, 1454, 1088, 1049 cm–1; δH (500 MHz, CDCl3) 7.17 (d, J = 8.3 Hz, 1H), 6.63 (dd, J = 8.5, 2.7 Hz, 
1H), 6.57 (d, J = 2.6 Hz, 1H), 2.88–2.79 (m, 2H), 2.62–2.54 (m, 1H), 2.48–2.44 (m, 1H), 2.32 (ddd, J = 12.0, 
12.0, 9.5 Hz, 1H), 2.26–2.20 (m, 2H), 1.94–1.88 (m, 2H), 1.84–1.72 (m, 2H), 1.67–1.60 (m, 2H), 1.57–1.25 
(m, 9H), 1.21 (s, 6H), 1.16–1.09 (m, 1H), 0.89 (s, 9H), 0.82 (ddd, J = 12.2, 8.5, 5.2 Hz, 1H), 0.72 (s, 3H), 
0.18 (s, 3H), 0.11 (s, 3H); δC (125 MHz, CDCl3) 153.4, 138.3, 132.7, 126.6, 115.2, 112.6, 90.4, 71.4, 48.8, 
48.6, 47.5, 43.9, 41.5, 38.9, 33.3, 31.9, 31.4, 29.8, 29.2, 29.1, 27.8, 27.3, 26.5, 25.9, 23.1, 18.3, 17.5, 18.3, 
17.5, –2.7, –3.0; m/z (EI) 512 (M), 453 (M–2Me–OH), 397 (M–TBS). 
 




(cis-21). To a solution of diphenylphosphine (0.99 mL, 5.7 mmol) in THF (4.0 mL) were added a 2.5 M 
solution of n-BuLi in hexane (2.3 mL, 5.8 mmol) and a solution of cis-20 (603 mg, 1.14 mmol) in THF (7.0 
mL). After the red solution was heated under reflux for 20 h, the resulting mixture was allowed to cool to 
room temperature. The mixture was diluted with EtOAc, washed with 10% HCl, saturated aqueous NaHCO3 
and brine, and dried over Na2SO4. Concentration under reduced pressure gave a pale yellow oil, which was 
purified by column chromatography (hexane/EtOAc 3:1) to give cis-21 (455 mg, 78%) as a white solid. 
Analytical sample was obtained by recrystallization from EtOAc as a white powder; C, 74.79; H, 10.44. 
C32H52O3Si requires C, 74.94; H, 10.22%; Mp 205–206 °C; [α]D20 +21.5 (c 1.00, THF); νmax (neat) 3314 (br), 
2974, 2882, 1088, 1045 cm–1; δH (500 MHz, CDCl3) 7.17 (d, J = 8.3 Hz, 1H), 6.64 (dd, J = 8.2, 2.4 Hz, 1H), 
6.57 (d, J = 2.3 Hz, 1H), 4.56 (s, 1H), 2.85–2.82 (m, 2H), 2.54 (ddd, J = 8.4, 8.4, 1.6 Hz, 1H), 2.35–2.28 (m, 
2H), 2.23–2.19 (m, 1H), 1.92–1.83 (m, 2H), 1.67–1.24 (m, 16H), 1.21 (s, 3H), 1.20 (s, 3H), 0.91 (s, 9H), 0.69 
(s, 3H), 0.24 (s, 3H), 0.10 (s, 3H); δC (125 MHz, THF-d8) 156.4, 138.1, 131.6, 126.7, 115.9, 113.6, 91.4, 69.7, 
49.3, 47.6, 45.5, 45.4, 41.0, 40.0, 39.2, 33.3, 32.7, 30.7, 30.6, 30.1, 29.4, 28.9, 27.2, 26.7, 23.8, 19.4, 15.3, –
1.0, –2.0; m/z (EI) 512 (M). 
 
4.2.27. Synthesis of 
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(6bS,8aS,8bS,9R,10aS,11aS,11bR)-9-(4-hydroxy-4-methylpentyl)-8a-methyl-1,2,6b,7,8,8a,9,10,10a,11,11a,11
b-dodecahydro-8bH-cyclobuta[3,4]cyclopenta[1,2-a]phenanthrene-4,8b-diol (trans-22). To a solution of 
trans-21 (120 mg, 0.234 mmol) in THF (1.0 mL) was added a 1.0 M solution of TBAF in THF (1.2 mL, 1.2 
mmol), and the solution was heated under reflux for 24 h. The resulting mixture was allowed to cool to room 
temperature, and purified by column chromatography (hexane/EtOAc 2:3) to give trans-22 (71 mg, 76%) as 
a white solid; Mp 197–198 °C; [α]D20 +12.8 (c 1.00, THF); νmax (THF) 3348 (br), 1454, 1361, 1288, 1222, 
1080 cm–1; δH (500 MHz, MeOH-d4) 7.09 (d, J = 8.6 Hz, 1H), 6.54 (dd, J = 8.3, 2.6 Hz, 1H), 6.48 (d, J = 1.7 
Hz, 1H), 2.81–2.76 (m, 2H), 2.62–2.55 (m, 1H), 2.42–2.23 (m, 3H), 2.21 (ddd, J = 11.1, 11.1, 3.0 Hz, 1H), 
2.02–1.91 (m, 3H), 1.80–1.65 (m, 3H), 1.56–1.33 (m, 9H), 1.161 (s, 3H), 1.158 (s, 3H), 0.86 (m, 1H), 0.80 (s, 
3H); δC (125 MHz, MeOH-d4) 155.9, 138.8, 132.6, 127.3, 116.0, 113.7, 89.2, 71.4, 50.0, 49.6, 48.9, 45.3, 
44.8, 42.4, 40.6, 33.9, 33.4, 32.6, 30.8, 29.3, 29.1, 29.0, 28.3, 27.7, 24.1, 17.3; m/z (EI) 398 (M), 380 (M–
H2O); HRMS (ESI): [M+Na]+, found 421.2720. C26H38O3Na requires 421.2713. 
 
4.2.28. Synthesis of 
(6bS,8aS,8bS,9S,10aS,11aS,11bR)-9-(4-hydroxy-4-methylpentyl)-8a-methyl-1,2,6b,7,8,8a,9,10,10a,11,11a,11
b-dodecahydro-8bH-cyclobuta[3,4]cyclopenta[1,2-a]phenanthrene-4,8b-diol (cis-22). To a solution of cis-21 
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(138 mg, 0.269 mmol) in THF (1.0 mL) was added a 1.0 M solution of TBAF in THF (2.2 mL, 2.2 mmol), 
and the solution was heated under reflux for 55 h. After cooling to room temperature, the resulting mixture 
was diluted with EtOAc, and washed with water. The aqueous layer was extracted with EtOAc, dried over 
Na2SO4, and concentrated in vacuo to give a yellow oil. The crude material was purified by column 
chromatography (hexane/EtOAc 1:1 to 2:3) to give cis-22 (70.0 mg, 66%) as a white solid; Mp 222–223 °C 
(dec.); [α]D20 +66.9 (c 1.00, THF); νmax (THF) 3298 (br), 2932, 1616, 1582, 1454, 1369, 1069 cm–1; δH (500 
MHz, DMSO-d6) 8.98 (s, 1H), 7.04 (d, J = 8.6 Hz, 1H), 6.50 (dd, J = 8.3, 2.0 Hz, 1H), 6.43 (d, J = 2.0 Hz, 
1H), 4.46 (s, 1H), 4.02 (s, 1H), 2.78–2.65 (m, 2H), 2.29–2.09 (m, 4H), 1.85–1.61 (m, 3H), 1.50–1.13 (m, 
14H), 1.04 (s, 6H), 0.67 (s, 3H); δC (125 MHz, DMSO-d6) 154.9, 137.2, 130.6, 126.0, 114.9, 112.7, 86.3, 
68.9, 48.8, 45.5, 44.2, 43.6, 40.2, 38.5, 36.4, 31.9, 31.5, 29.5, 29.4, 29.2, 28.8, 27.4, 25.9, 22.1, 14.1; m/z (EI) 
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